We have previously reported that DiAcSpm is frequently elevated in patients with various cancers, including colorectal, breast, lung, prostate, testicular, renal, and pelvic cancer, with very low false-negative incidence [ 11, 26].
False negative screening results and incidence of interval cancers have an important influence on the success of breast cancer screening programmes.
Considering these late reports, we revised our series and those reported in Literature to value the incidence of inguinal MTS T-stage related and the incidence of false negative (FN) SLNB in order to confirm or exclude indication to SLNB in all T stages for patients affected by anal cancer.
This original study reports an update of personal and previous published series, which were compared with Literature to value the incidence of inguinal metastases T-stage related and the overall incidence of false negative inguinal metastases at sentinel node.
With more slowly declining age-specific incidence, higher false negative measurement rates provide a better description of the observed pattern.
However, MRI (A) assessment has associated drawbacks, including a relatively high incidence of false negative [FN] (i.e. Pathology shown to be negative on MRI when in actuality pathology is present) and false positive [FP] (i.e. Pathology shown to be present on MRI when in actuality there is none) findings.
However, the rate of SN identification and the incidence of false negative cases reported in literature vary greatly The average rate of SN identification using blue dye or radioactive colloids is more than 90%, but results ranging from 65%to98%8% have been reported [ 1].
13 After 11 weeks the incidence of false negative results was considerably lower (at 1/956 between 11-13 weeks; 0.1%, 0.02% to 0.59%) and did not decrease between 11 and 24 weeks, in line with recent evidence that concentrations of cell free fetal DNA increase only minimally between 10 and 20 weeks' gestation.
Our proportion of false positives therefore appears low, and although we did not assess the proportion of false negatives, our observed incidence is in line with the published literature, which should entail that our approach is valid for the proportion of herpes zoster cases which have merited/triggered health care attention.
The SLNB was less effective when: SLNB false negative (FN) rate >13% 5-year incidence of axillary recurrence after an SLNB FN>19% risk of an SLNB-positive result >48% lymphoedema prevalence after ALND <14% or lymphoedema utility decrement <0.012.
Associated with this is a substantial reduction in the predicted incidence of false positive and false negative results.
